AntiCD2

AntiCD2 refers to antibodies or other therapeutic agents that target the CD2 cell adhesion molecule, which is predominantly expressed on T lymphocytes and natural killer (NK) cells. CD2 participates in adhesion to its ligand LFA-3 (CD58) and plays a role in T cell activation and immune cell interactions. By binding CD2, antiCD2 agents can interfere with CD2–LFA-3 interactions and modulate immune responses, and in some cases may mediate depletion of CD2-expressing cells through mechanisms such as antibody-dependent cellular cytotoxicity or complement activation.

Mechanistically, antiCD2 antibodies can act by blocking costimulatory signals required for full T cell activation, by inhibiting cell-cell adhesion, or by targeting CD2-expressing cells for removal from circulation. This makes them useful as research tools to study T cell function and as immunomodulatory agents in clinical settings where dampening of T cell activity is desirable.

Clinical use and development have focused on transplantation and autoimmune diseases, where reducing T cell–mediated responses can help prevent graft rejection or dampen pathogenic autoimmunity. Several antiCD2 monoclonal antibodies have been explored in early-phase trials, with development in some indications advancing while others were discontinued or not pursued further due to safety or efficacy considerations. To date, antiCD2 approaches have not become standard-of-care therapies.

See also: CD2, LFA-3 (CD58), monoclonal antibodies, T cell activation.